The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Toll-Like Receptor 4 Is Involved in the Development of Fructose-Induced Hepatic Steatosis in Mice†
Open accessAbstract
A link between dietary fructose intake, gut-derived endotoxemia, and nonalcoholic fatty liver disease (NAFLD) has been suggested by the results of human and animal studies. To further investigate the role of gut-derived endotoxin in the onset of fructose-induced NAFLD, Toll-like receptor (TLR-) 4-mutant (C3H/HeJ) mice and wildtype (C3H/HouJ) mice were either fed plain water or water enriched with 30% fructose for 8 weeks. Hepatic steatosis, plasma alanine aminotransferase (ALT), and markers of insulin resistance as well as portal endotoxin levels were determined. Hepatic levels of myeloid differentiation factor 88 (MyD88), interferon regulatory factor (IRF) 3 and 7, and tumor necrosis factor alpha (TNFα) as well as markers of lipid peroxidation were assessed. Chronic intake of 30% fructose solution caused a significant increase in hepatic steatosis and plasma ALT levels in wildtype animals in comparison to water controls. In fructose-fed TLR-4 mutant mice, hepatic triglyceride accumulation was significantly reduced by ≈40% in comparison to fructose-fed wildtype mice and plasma ALT levels were at the level of water-fed controls. No difference in portal endotoxin concentration between fructose-fed wildtype and TLR-4-mutant animals was detected. In contrast, hepatic lipid peroxidation, MyD88, and TNFα levels were significantly decreased in fructose-fed TLR-4-mutant mice in comparison to fructose-fed wildtype mice, whereas IRF3 and IRF7 expression remained unchanged. Markers of insulin resistance (e.g., plasma TNFα, retinol binding protein 4, and hepatic phospho-AKT) were only altered in fructose-fed wildtype animals. Conclusion: Taken together, these data further support the hypothesis that in mice the onset of fructose-induced NAFLD is associated with intestinal bacterial overgrowth and increased intestinal permeability, subsequently leading to an endotoxin-dependent activation of hepatic Kupffer cells. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B. (2005) · Nature · doi:10.1038/nature03711 · Cited by 2,086
Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects
Graham, T. E., Yang, Q., Blüher, M., Hammarstedt, A., Ciaraldi, T. P., Henry, R. R., Wason, C. J., Oberbach, A., Jansson, P.-A., Smith, U., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054862 · Cited by 1,319
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005) · Hepatology · doi:10.1002/hep.20734 · Cited by 1,263
Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
Brun, P., Castagliuolo, I., Leo, V. D., Buda, A., Pinzani, M., Palù, G., & Martines, D. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2006 · Cited by 864
Fructose consumption as a risk factor for non-alcoholic fatty liver disease
Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J. L., Diehl, A. M., Johnson, R. J., & Abdelmalek, M. F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.011 · Cited by 863
Fructose, insulin resistance, and metabolic dyslipidemia
Basciano, H., Federico, L., & Adeli, K. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-5 · Cited by 832
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722
Cited by
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
Self-citationNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Cani, P. D., Osto, M., Geurts, L., & Everard, A. (2012) · Gut Microbes · doi:10.4161/gmic.19625 · Cited by 864
Abdelmalek, M. F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R. J., & Diehl, A. M. (2010) · Hepatology · doi:10.1002/hep.23535 · Cited by 770
Rehman, K., & Akash, M. S. H. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0303-y · Cited by 671
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666
Obesity, Diabetes, and Gut Microbiota
Musso, G., Gambino, R., & Cassader, M. (2010) · Diabetes Care · doi:10.2337/dc10-0556 · Cited by 665
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Sanders, F. W. B., & Griffin, J. L. (2016) · Biological Reviews · doi:10.1111/brv.12178 · Cited by 539
Gut microbiota and metabolic syndrome
Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., & Colecchia, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16079 · Cited by 534
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Animal models of nonalcoholic fatty liver disease
Hebbard, L., & George, J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.191 · Cited by 499
Pierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 457
Cirrhosis-associated immune dysfunction
Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., & Álvarez-Mon, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00520-7 · Cited by 447
Charlton, M., Krishnan, A., Viker, K., Sanderson, S., Cazanave, S., McConico, A., Masuoko, H., & Gores, G. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00145.2011 · Cited by 444
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
Seki, E., & Schnabl, B. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.219691 · Cited by 442
Dekker, M. J., Su, Q., Baker, C., Rutledge, A. C., & Adeli, K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00283.2010 · Cited by 420
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. V., Gan, L., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 398
Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide
Van Herck, M., Vonghia, L., & Francque, S. (2017) · Nutrients · doi:10.3390/nu9101072 · Cited by 392
Fang, Y.-L., Chen, H., Wang, C.-L., & Liang, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i27.2974 · Cited by 379
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 376
Kohli, R., Kirby, M., Xanthakos, S. A., Softic, S., Feldstein, A. E., Saxena, V., Tang, P. H., Miles, L., Miles, M. V., Balistreri, W. F., et al. (2010) · Hepatology · doi:10.1002/hep.23797 · Cited by 376
Gut microbiota, probiotics and diabetes
Gomes, A. C., Bueno, A. A., de Souza, R. G. M., & Mota, J. F. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-60 · Cited by 363
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases
Soares, J.-B., Pimentel-Nunes, P., Roncon-Albuquerque, R., & Leite-Moreira, A. (2010) · Hepatology International · doi:10.1007/s12072-010-9219-x · Cited by 367
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease
Miura, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7381 · Cited by 355
Wong, V. W.-S., Tse, C.-H., Lam, T. T.-Y., Wong, G. L.-H., Chim, A. M.-L., Chu, W. C.-W., Yeung, D. K.-W., Law, P. T.-W., Kwan, H.-S., Yu, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062885 · Cited by 342
Endo, H., Niioka, M., Kobayashi, N., Tanaka, M., & Watanabe, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063388 · Cited by 336
Gut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
Stojsavljević, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18070 · Cited by 325
Excessive intake of sugar: An accomplice of inflammation
Ma, X., Nan, F., Liang, H., Shu, P., Fan, X., Song, X., Hou, Y., & Zhang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988481 · Cited by 314
Gut Microbiota, Intestinal Permeability, Obesity‐Induced Inflammation, and Liver Injury
Frazier, T. H., DiBaise, J. K., & McClain, C. J. (2011) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607111413772 · Cited by 306
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis
Guo, J., & Friedman, S. L. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-21 · Cited by 311
Xue, L., He, J., Gao, N., Lu, X., Li, M., Wu, X., Liu, Z., Jin, Y., Liu, J., Xu, J., et al. (2017) · Scientific Reports · doi:10.1038/srep45176 · Cited by 305
In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
Kanuri, G., & Bergheim, I. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611963 · Cited by 290
Self-citationDietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study
Racine, A., Carbonnel, F., Chan, S. S. M., Hart, A. R., Bueno-de-Mesquita, H. B., Oldenburg, B., van Schaik, F. D. M., Tjønneland, A., Olsen, A., Dahm, C. C., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000638 · Cited by 276
Horst, E. A., Kvidera, S. K., & Baumgard, L. H. (2021) · Journal of Dairy Science · doi:10.3168/jds.2021-20330 · Cited by 263
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
Anstee, Q. M., Seth, D., & Day, C. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.037 · Cited by 254
Cho, Y., Kim, D., Seo, W., Gao, B., Yoo, S., & Song, B. (2021) · Hepatology · doi:10.1002/hep.30652 · Cited by 254
Ye, D., Li, F. Y. L., Lam, K. S. L., Li, H., Jia, W., Wang, Y., Man, K., Lo, C. M., Li, X., & Xu, A. (2012) · Gut · doi:10.1136/gutjnl-2011-300269 · Cited by 206
Damms-Machado, A., Louis, S., Schnitzer, A., Volynets, V., Rings, A., Basrai, M., & Bischoff, S. C. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.131110 · Cited by 195
Self-citationContribution of Gut Bacteria to Liver Pathobiology
Son, G., Kremer, M., & Hines, I. N. (2010) · Gastroenterology Research and Practice · doi:10.1155/2010/453563 · Cited by 183
Nonalcoholic steatohepatitis: a search for factual animal models
Sanches, S. C. L., Ramalho, L. N. Z., Augusto, M. J., da Silva, D. M., & Ramalho, F. S. (2015) · BioMed Research International · doi:10.1155/2015/574832 · Cited by 174
Spruss, A., Kanuri, G., Stahl, C., Bischoff, S. C., & Bergheim, I. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.75 · Cited by 168
Self-citationPathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Toll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158
Meli, R., Mattace Raso, G., & Calignano, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00177 · Cited by 137
The Emerging Role of B Cells in the Pathogenesis of NAFLD
Barrow, F., Khan, S., Wang, H., & Revelo, X. S. (2021) · Hepatology · doi:10.1002/hep.31889 · Cited by 126
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120
“Increased plasma concentration of tumor necrosis factor (TNF)-α, portal lipopolysaccharide (LPS), and myeloid differentiation primary response gene (MyD)88 have observed these mice [37].”
Barazzoni, R., Deutz, N. E. P., Biolo, G., Bischoff, S., Boirie, Y., Cederholm, T., Cuerda, C., Delzenne, N., Leon Sanz, M., Ljungqvist, O., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.010 · Cited by 112
Self-citationSong, K., Kwon, H., Han, C., Chen, W., Zhang, J., Ma, W., Dash, S., Gandhi, C. R., & Wu, T. (2020) · Hepatology · doi:10.1002/hep.30990 · Cited by 110
Cho, Y.-E., Yu, L.-R., Abdelmegeed, M. A., Yoo, S.-H., & Song, B.-J. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.005 · Cited by 99
Gut microbiota in health and disease: an overview focused on metabolic inflammation
Nagpal, R., Kumar, M., Yadav, A. K., Hemalatha, R., Yadav, H., Marotta, F., & Yamashiro, Y. (2016) · Beneficial Microbes · doi:10.3920/bm2015.0062 · Cited by 97
Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis
Heier, E.-C., Meier, A., Julich-Haertel, H., Djudjaj, S., Rau, M., Tschernig, T., Geier, A., Boor, P., Lammert, F., & Lukacs-Kornek, V. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.008 · Cited by 94
Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer
Sinclair, P., Brennan, D. J., & le Roux, C. W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0057-y · Cited by 91
Heida, A., Gruben, N., Catrysse, L., Koehorst, M., Koster, M., Kloosterhuis, N. J., Gerding, A., Havinga, R., Bloks, V. W., Bongiovanni, L., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101349 · Cited by 78
Cho, Y.-E., & Song, B.-J. (2018) · Redox Biology · doi:10.1016/j.redox.2018.07.012 · Cited by 78
Crescenzo, R., Mazzoli, A., Di Luccia, B., Bianco, F., Cancelliere, R., Cigliano, L., Liverini, G., Baccigalupi, L., & Iossa, S. (2017) · Food & Nutrition Research · doi:10.1080/16546628.2017.1331657 · Cited by 63
Zhang, R.-N., Pan, Q., Zhang, Z., Cao, H.-X., Shen, F., & Fan, J.-G. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.15(5)2015.27909 · Cited by 56
Fang, W., Deng, Z., Benadjaoud, F., Yang, C., & Shi, G.-P. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.011 · Cited by 40
Probiotic antigens stimulate hepatic natural killer T cells
Liang, S., Webb, T., & Li, Z. (2014) · Immunology · doi:10.1111/imm.12180 · Cited by 39
Song, C., Lv, W., Li, Y., Nie, P., Lu, J., Geng, Y., Heng, Z., & Song, L. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00631-7 · Cited by 28
Metadata
- Authors
- Spruss, A., Kanuri, G., Wagnerberger, S., Haub, S., Bischoff, S. C., & Bergheim, I.
- Venue
- Hepatology
- Published
- 2009-10
- Volume
- 50
- Issue
- 4
- Pages
- 1094-1104
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1990061996
- Cited by
- 562
- References
- 35
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.